- In March 2024, Thermo Fisher Scientific announced the expansion of its Fetal Bovine Serum (FBS) production facility in the U.K. The new facility, which has a production capacity increase of 25%, is expected to meet the growing demand from biotechnology and pharmaceutical companies for high-quality FBS. The investment of USD 30 million will also support advancements in cell culture technology and vaccine development.
- In February 2024, Sigma-Aldrich launched a new line of FBS sourced from BSE-free regions, aimed at providing the highest standards of quality and safety for use in clinical research and vaccine production. The serum, which is certified for pharmaceutical-grade applications, has been tested for traceability and regulatory compliance to meet increasing demand in Asia-Pacifican market.
- In December 2023, Lonza Group, a leading contract manufacturer of biologics, expanded its cell culture media production capabilities in Switzerland to include a dedicated Fetal Bovine Serum purification process. This development will enhance the company’s ability to provide high-quality FBS for growing applications in stem cell research, gene therapy, and biologics production.
- In November 2022, Hyclone Laboratories (a part of Thermo Fisher Scientific) secured a significant partnership with several Asia-Pacifican biotechnology firms to ensure a stable supply of high-quality FBS. This partnership, aimed at meeting the rising demand in the Asia-Pacifican biopharma sector, includes the distribution of custom-tailored FBS solutions for regenerative medicine and clinical research.
